Article
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.
Oncotarget - 26 Jan 2016
Nanjo Shigeki, Ebi Hiromichi, Arai Sachiko, Takeuchi Shinji, Yamada Tadaaki, Mochizuki Satsuki, Okada Yasunori, Nakada Mitsutoshi, Murakami Takashi, Yano Seiji
Abstract excerpt
Leptomeningeal carcinomatosis (LMC) remarkably decreases the quality of life of EGFR-mutant lung cancer patients. In contrast to the lesions outside the central nervous system (CNS), molecular mechanisms of EGFR tyrosine kinase inhibitor (TKI) resistance in CNS lesions including LMC are largely unknown. In this study, we established an in vivo imaging model for LMC with EGFR mutant lung cancer cell lines...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.